Your browser doesn't support javascript.
loading
Diagnostic criteria for apathy in neurocognitive disorders.
Miller, David S; Robert, Philippe; Ereshefsky, Larry; Adler, Lawrence; Bateman, Daniel; Cummings, Jeff; DeKosky, Steven T; Fischer, Corinne E; Husain, Masud; Ismail, Zahinoor; Jaeger, Judith; Lerner, Alan J; Li, Abby; Lyketsos, Constantine G; Manera, Valeria; Mintzer, Jacobo; Moebius, Hans J; Mortby, Moyra; Meulien, Didier; Pollentier, Stephane; Porsteinsson, Anton; Rasmussen, Jill; Rosenberg, Paul B; Ruthirakuhan, Myuri T; Sano, Mary; Zucchero Sarracini, Carla; Lanctôt, Krista L.
Afiliação
  • Miller DS; Signant Health, Blue Bell, Pennsylvania, USA.
  • Robert P; Cognition Behaviour Technology Lab, Université Côte d'Azur, Nice, France.
  • Ereshefsky L; Association Innovation Alzheimer, Nice, France.
  • Adler L; Centre Memoire, Centre Hospitalier Universitaire de Nice, Nice, France.
  • Bateman D; Follow the Molecule, Marina del Rey, California, USA.
  • Cummings J; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • DeKosky ST; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Fischer CE; Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Nevada, USA.
  • Husain M; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA.
  • Ismail Z; Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
  • Jaeger J; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Lerner AJ; Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Li A; Department of Experimental Psychology, University of Oxford, Oxford, UK.
  • Lyketsos CG; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Manera V; Oxford NIHR Biomedical Research Centre, Oxford, UK.
  • Mintzer J; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  • Moebius HJ; CognitionMetrics, Wilmington, Delaware, USA.
  • Mortby M; University Hospitals - Case Western Reserve University, Cleveland, Ohio, USA.
  • Meulien D; Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Pollentier S; Johns Hopkins University, Baltimore, Maryland, USA.
  • Porsteinsson A; Cognition Behaviour Technology Lab, Université Côte d'Azur, Nice, France.
  • Rasmussen J; Association Innovation Alzheimer, Nice, France.
  • Rosenberg PB; Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA.
  • Ruthirakuhan MT; Moebius-Consult, Baar, Switzerland.
  • Sano M; UNSW Ageing Futures Institute, The University of New South Wales, Sydney, Australia.
  • Zucchero Sarracini C; Clinical Research and Development, H. Lundbeck A/S, Valby, Denmark.
  • Lanctôt KL; Boehringer Ingelheim Pharma GmbH & Co KG, CNS Diseases Research, Biberach an der Riss, Germany.
Alzheimers Dement ; 17(12): 1892-1904, 2021 12.
Article em En | MEDLINE | ID: mdl-33949763
ABSTRACT

INTRODUCTION:

Apathy is common in neurocognitive disorders (NCD) but NCD-specific diagnostic criteria are needed.

METHODS:

The International Society for CNS Clinical Trials Methodology Apathy Work Group convened an expert group and sought input from academia, health-care, industry, and regulatory bodies. A modified Delphi methodology was followed, and included an extensive literature review, two surveys, and two meetings at international conferences, culminating in a consensus meeting in 2019.

RESULTS:

The final criteria reached consensus with more than 80% agreement on all parts and included limited to people with NCD; symptoms persistent or frequently recurrent over at least 4 weeks, a change from the patient's usual behavior, and including one of the following diminished initiative, diminished interest, or diminished emotional expression/responsiveness; causing significant functional impairment and not exclusively explained by other etiologies.

DISCUSSION:

These criteria provide a framework for defining apathy as a unique clinical construct in NCD for diagnosis and further research.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnica Delphi / Transtornos Neurocognitivos / Consenso / Prova Pericial / Apatia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnica Delphi / Transtornos Neurocognitivos / Consenso / Prova Pericial / Apatia Idioma: En Ano de publicação: 2021 Tipo de documento: Article